Avanos Medical (AVNS) to Post Quarterly Earnings on Monday

Avanos Medical (NYSE:AVNS) is expected to announce its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of $0.16 per share and revenue of $173.00 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 12:30 PM ET.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.16 by $0.06. The business had revenue of $182.20 million during the quarter, compared to the consensus estimate of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 EPS. On average, analysts expect Avanos Medical to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Avanos Medical Stock Performance

Shares of Avanos Medical stock opened at $24.99 on Monday. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -15.52 and a beta of 1.57. The business has a 50-day moving average price of $24.94 and a 200-day moving average price of $19.77. The company has a quick ratio of 1.40, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. Avanos Medical has a twelve month low of $9.30 and a twelve month high of $25.49.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on AVNS shares. Zacks Research upgraded Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, June 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, July 20th. Finally, Wall Street Zen cut Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Avanos Medical has a consensus rating of “Reduce”.

Institutional Trading of Avanos Medical

Hedge funds have recently made changes to their positions in the business. Armistice Capital LLC lifted its holdings in shares of Avanos Medical by 22.8% in the 3rd quarter. Armistice Capital LLC now owns 2,500,000 shares of the company’s stock valued at $28,900,000 after acquiring an additional 464,000 shares during the last quarter. State Street Corp increased its stake in Avanos Medical by 2.8% during the fourth quarter. State Street Corp now owns 1,954,785 shares of the company’s stock worth $21,952,000 after acquiring an additional 53,523 shares during the last quarter. Geode Capital Management LLC raised its position in Avanos Medical by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company’s stock valued at $12,180,000 after purchasing an additional 16,980 shares during the period. Charles Schwab Investment Management Inc. raised its position in Avanos Medical by 20.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company’s stock valued at $11,687,000 after purchasing an additional 176,716 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Avanos Medical by 312.4% in the 3rd quarter. Millennium Management LLC now owns 896,242 shares of the company’s stock valued at $10,361,000 after purchasing an additional 678,898 shares during the last quarter. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.